Spectrum seeks removal of bioscan requirement for Zevalin
This article was originally published in Scrip
Executive Summary
Spectrum Pharmaceuticals is seeking to have removed from the labelling of its non-Hodgkin's lymphoma drug (NHL) Zevalin (ibritumomab tiuxetan) a requirement for a certain type of bioscan known as an i-111 pretreatment imaging evaluation.